| MERZ PHARMA GmbH & CO. KGaA Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136005 | ELTOPRAZINE FOR THE TREATMENT OF ANXIETY - The present invention relates to the treatment of an individual afflicted with certain forms of anxiety, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof | 05-31-2012 |
| 20120130130 | METHOD OF PREPARING NERAMEXANE - The method of producing a salt of 1-amino-1,3,3,5,5-pentamethylcyclohexane comprising steps (i) to (v):
| 05-24-2012 |
| 20120123166 | METHOD OF PREPARING 1-HYDROXY-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE - Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane comprising step (ii): (ii) converting 3,3,5,5-tetramethylcyclohexanone to 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane by using methylmagnesium chloride. 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane may be used for preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof. | 05-17-2012 |
| 20120116125 | METHOD OF PREPARING NERAMEXANE - Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane or pharmaceutically acceptable salt thereof, comprising at least two steps selected from the following steps (i) to (iv):
| 05-10-2012 |
| 20120107362 | NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY - The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain of the neurotoxin polypeptide as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments. | 05-03-2012 |
| 20120101172 | LIQUID OR POURABLE PROTEOSOME-FORMING BATH AND SHOWER CONCENTRATES, GALENIC APPLICATION PRODUCTS THEREOF, AND THEIR USE - The invention relates to balneological preparations, especially bath and shower preparations, which, as a pourable or liquid premixture concentrate, contain liposome-forming components, such as phospholipids, in addition to natural and/or synthetic lipids, and are also provided as mixtures containing primarily vegetable proteins, surfactants, and optional additives. When entering in contact with an excess of water, the stable systems directly form skin-active proteoliposomes having a catalytic activity for enhancing transfer of active ingredients into the skin. The stable systems can be used directly or in diluted or solid forms of application (such as lipid-containing proteasome shower preparation, proteasome bath powder, and the like). | 04-26-2012 |
| 20120093866 | FORMULATION FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENT - The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, and wherein the formulation is free of stabilizing proteins. | 04-19-2012 |
| 20120088732 | THERAPEUTIC COMPOSITION COMPRISING A BOTULINUM NEUROTOXIN - A pharmaceutical preparation comprising one of the botulinum neurotoxins from | 04-12-2012 |
| 20120004179 | MEANS AND METHODS FOR MANUFACTURING HIGHLY PURE NEUROTOXIN - The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 16 and to methods for the manufacture of such antibodies. Moreover, the present invention relates to a composition comprising processed neurotoxin polypeptide free of unprocessed or partially processed neurotoxin polypeptide and a method for manufacturing said neurotoxin polypeptide based on the antibodies of the invention. The present invention also relates to the use of the aforementioned antibody for separating processed neurotoxin polypeptides from unprocessed or partially processed neurotoxin polypeptides or for determining unprocessed or partially processed neurotoxin polypeptides. The present invention relates to a method for the manufacture of a medicament. | 01-05-2012 |
| 20110294890 | Neramexane for the treatment or prevention of inner ear disorders - The present invention relates to a method of treatment or prevention of an inner ear disorder in a female comprising administering a therapeutically effective amount of neramexane or a pharmaceutically acceptable salt thereof to a female. | 12-01-2011 |
| 20110288336 | METHOD FOR PRODUCING MEMANTINE - Method for producing 1-amino-3,5-dimethyladamantane or a salt thereof, comprising: (i) heating 1-formamido-3,5-dimethyladamantane with a base in a protic solvent. | 11-24-2011 |
| 20110288105 | ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA - The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in Parkinson's patients, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof. | 11-24-2011 |
| 20110282100 | PROCESS FOR PREPARING MEMANTINE - The present invention relates to a process for preparing memantine, or a pharmaceutically acceptable salt thereof (e.g., memantine hydrochloride), which is substantially free of impurities. | 11-17-2011 |
| 20110263900 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD - The present invention pertains to process for the amidation of a substituted 1-bromo-adamantane comprising a step (0) of reacting a substituted adamantane with an excess of bromine to obtain a 1-bromo-adamantane and a step (i) of reacting said substituted 1-bromo-adamantane with an amide, wherein the substituted 1-bromo-adamantane is used in the form of a mixture comprising bromine as obtained in step (0), wherein in step (0) a bromine:substituted adamantane molar ratio of from [2.5:1] to less than [5:1] is employed. | 10-27-2011 |
| 20110250270 | Compositions containing a capillary-active system with application-relevant diffferentiability and their use - A composition that has a capillary-active system C optionally containing a capillary activator system CA consisting of drugs that increase blood flow, stabilize the vascular wall, and/or dilate the blood vessels; and/or a capillary-protective system CP comprising drugs for endothelial stabilization, lipoprotein protection, and for stabilization of leukocytes/platelets; and/or a capillary energy supply system CE comprising redox systems and cofactors in energy provision and energy carriers. This system C is combined with a selective action system S. The compositions are useful, systemically or enterally, especially for the selective control, for example, of structural changes, functional disturbances of the target organs in question (hair, skin, cerebrum, skeleton, muscles, gastrointestinal tract, eyes) as supplements (food supplements, supplementary balanced diet, dietary components), or pharmaceutical agents. | 10-13-2011 |
| 20110217287 | Therapeutic composition comprising a botulinum neurotoxin - A pharmaceutical preparation comprising one of the botulinum neurotoxins from | 09-08-2011 |
| 20110212956 | Pyrazolopyrimidines for treating CNS disorders - Substituted pyrazolopyrimidine derivatives of formula (I) | 09-01-2011 |
| 20110200664 | LIPOSOMAL STRUCTURES FORMING ISOMETRIC AGGLOMERATES, ESPECIALLY BATH BEADS, THE PRODUCTION AND USE THEREOF - The present invention relates to isometric agglomerates of an essentially spherically shaped form, especially bath beads, and the cosmetic, therapeutic and hygienic use thereof. The invention is especially concerned with agglomerates on the basis of carriers of natural origin such as collagen, gelatine, starch, cellulose or urea, which comprise both lipids and vesicle forming agents as well as emulsifying components and optionally additives, without impairing the stability or activity thereof. The agglomerates when contacting water, especially in a bathing, will form liposomal mono- up to multi-layer structures thereby enabling an improved transport of active compounds. This will result in an improved balneological/or therapeutic action as well as a caring effect in the sense of a reconstruction of the skin barrier function. | 08-18-2011 |
| 20110189158 | CLOSTRIDIAL NEUROTOXINS WITH ALTERED PERSISTENCY - The invention relates to a polypeptide comprising:
| 08-04-2011 |
| 20110178179 | 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT IN TINNITUS - The present invention relates to the treatment of an individual afflicted with cognitive impairment associated with tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 07-21-2011 |
| 20110091503 | Therapeutic composition with a botulinum neurotoxin - The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from | 04-21-2011 |
| 20110086916 | INTERVAL THERAPY FOR THE TREATMENT OF TINNITUS - The present invention relates to interval and/or maintenance therapy employing 1-amino-alkylcyclohexane derivatives (e.g., neramexane or a pharmaceutically acceptable salt thereof) for the treatment of an individual afflicted with tinnitus. | 04-14-2011 |
| 20110077304 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS. - The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 03-31-2011 |
| 20110039942 | TITRATION PACKAGE - The present invention relates to a titration package for providing at least one pharmaceutical composition in at least two different dosages. The titration package comprises at least two sets. Each set comprises at least three individually addressable regions. Each addressable region preferably comprises or is represented by a pharmaceutical composition, preferably a tablet. The dosage of the pharmaceutical composition is the same within each of the at least two sets (“common dosage”), while the dosages of the pharmaceutical compositions are different for one of the at least two sets compared to at least one other of the at least two sets. The arrangement of the at least two sets is not a matrix-like arrangement. | 02-17-2011 |
| 20110034563 | COMPARTMENT-SPECIFIC PLANT EXTRACT COMBINATION OF GINKGO BILOBA EXTRACT AND GINSENG EXTRACT HAVING A TANDEM EFFECT - The invention relates to a plant extract combination of | 02-10-2011 |
| 20110003820 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE - The invention relates to pyrazolopyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders. | 01-06-2011 |
| 20100331259 | USE OF A NEUROTOXIC COMPONENT OF A CLOSTRIDIUM BOTULINUM TOXIN COMPLEX TO REDUCE OR PREVENT SIDE EFFECTS. - Use of a neurotoxic component of a | 12-30-2010 |
| 20100298442 | 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists - Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating conditions which are alleviated by the employment of a 5HT3 or neuronal nicotinic receptor antagonist. | 11-25-2010 |
| 20100298441 | TITRATION PACKAGE FOR NERAMEXANE AND ITS USE IN THE TREATMENT OF AN INNER EAR DISORDER - The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus. | 11-25-2010 |
| 20100298440 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF HEARING LOSS - The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 11-25-2010 |
| 20100247689 | Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue - The invention relates to a novel agent containing fat (oil), which contains onion extract, in addition to the production and use thereof for caring, preventing or treating damaged skin tissue, such as after operations, biopsies, wounds, burns and other accidents, and especially scarred tissue, stretch marks, degenerative skin conditions and others. The agent is characterised in that the base thereof is based on oil, which can be used to produce, for example, cream, lotion, fluid, massage, or balm based products which contain fail (oil). Surprisingly, the onion extract, which contains water, alcohol or water-alcohol, can be integrated into a base containing oil without the effectiveness thereof being reduced or a phase separation being produced. The effectiveness thereof could be proved when the medical application thereof was monitored. | 09-30-2010 |
| 20100234358 | NERAMEXANE FOR THE TREATMENT OF NYSTAGMUS - The present invention relates to the treatment of an individual diagnosed with nystagmus comprising administering to the individual an effective amount of a 1-aminoalkylcyclohexane derivative, for example neramexane or a pharmaceutically acceptable salt thereof, such as neramexane mesylate. | 09-16-2010 |
| 20100227852 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors - The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. | 09-09-2010 |
| 20100197792 | 1-Amino-Alkylcyclohexane derivatives for the treatment of inflammatory skin diseases - The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 08-05-2010 |
| 20100190751 | NOVEL COMBINATION OF NERAMEXANE FOR TREATMENT OF NERORDEGENERATIE DISORDERS - The present invention relates to combinations comprising neramexane and a Glutamate Release Inhibitor (GRI) and the use of such combinations in the treatment of neurodegenerative disorders. | 07-29-2010 |
| 20100098766 | USE OF AN AQUEOUS MICRO-EMULSION FOR THE PREPARATION OF A FORMULATION FOR THE TREATMENT OF ADIPOSE DISEASES - Use of a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and good release behaviour of active substances. | 04-22-2010 |
| 20100076073 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders - The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses. | 03-25-2010 |
| 20100035995 | Compositions comprising Cyclohexylamines and Aminoadamantanes - The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container. | 02-11-2010 |
| 20100004216 | Medicinal lipolysis of accumulation of fat - Aqueous preparations comprising at least one phospholipid or at least one bile acid and a component assisting degradation of fat such as riboflavin and water are suitable for producing medicaments for removing subcutaneous accumulations of fat and lead to regression of diet-resistant fat pads. | 01-07-2010 |
| 20090299097 | Method for Producing 1-Formamido-3,5-Dimethyladamantane - The invention relates to a method for producing 1-formamido-3,5-dimethyladamantane in only two reaction steps by direct formamide formation of 1,3-dimethyladamantane, the 1,3-dimethyladamantane being reacted with formamide in concentrated acids. | 12-03-2009 |
| 20090124659 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors - The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. | 05-14-2009 |
| 20090081259 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect - The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane. | 03-26-2009 |
| 20090028906 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in a solid form - The present invention relates to a method for providing a muscle relaxant at temperatures above 20° C., wherein said muscle relaxant is a solid dry composition comprising the neurotoxic component of botulinum toxin free of complexing proteins. | 01-29-2009 |
| 20090010965 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin - The present invention provides a method for providing a muscle relaxant, wherein said muscle relaxant is a reconstituted solution comprising the neurotoxic component of botulinum toxin free of complexing proteins, which exhibits at least one of the following characteristics, more preferably all characteristics a) to d):
| 01-08-2009 |
| 20080279896 | Treatment of movement disorders by a combined use of chemodenervating agent and automated movement therapy - The present invention relates to a method of treating a movement disorder in a patient, the method comprising administering a medicament comprising an effective amount of chemodenervating agent to the patient, wherein the patient is subjected to a muscle stimulation therapy, for example an movement therapy or an muscle activation therapy, and the medicament is administered prior to and/or during and/or after the movement therapy and a kit for the treatment of patients suffering from movement disorders comprising a medicament comprising an effective amount of a chemodenervating agent, and a device for carrying out automated movement therapy. | 11-13-2008 |
| 20080268055 | Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases - A method for treating a patient suffering from an adipose tissue disease and/or a condition associated with adipose tissue disease, comprising administering a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water in an amount effective for treatment of the disease and/or condition. | 10-30-2008 |
